Pubmed (TDAH) du 31/05/26
1. Yang S, Kim JW, Lee S, Kwon J. Neurophysiological Effects of a Digital Therapeutic for Attention-deficit/Hyperactivity Disorder: A Quantitative Electroencephalography Analysis of Theta-Gamma Coupling. Clin Psychopharmacol Neurosci. 2026; 24(2): 344-52.
OBJECTIVE: This study evaluated the neurophysiological effects of ADAM-101, a game-based digital therapeutic, in children with attention-deficit/hyperactivity disorder (ADHD) using quantitative electroencephalography (qEEG). We focused on theta-gamma coupling (TGC), a neural synchrony marker linked to attentional control and executive function. METHODS: Eighteen children with ADHD were randomized to an intervention group (n = 9; pharmacotherapy + ADAM-101) or a control group (n = 9; pharmacotherapy only). qEEG was recorded at baseline and after 4 weeks. TGC in the prefrontal cortex was quantified using the synchronization index method with gamma frequencies subdivided into 3-Hz bins between 30 and 51 Hz. RESULTS: The intervention group showed increased prefrontal TGC following the 4-week program, while the control group demonstrated decreases. These findings suggest that gamified cognitive training via ADAM-101 may enhance cross-frequency coupling mechanisms underlying attention and cognitive regulation. CONCLUSION: ADAM-101, when combined with pharmacotherapy, improved neural synchrony in pediatric ADHD, as evidenced by increased prefrontal TGC. This exploratory trial supports the potential of digital therapeutics as adjunctive interventions targeting neurophysiological mechanisms of attentional control. Larger studies are needed to validate these preliminary results.
Lien vers le texte intégral (Open Access ou abonnement)
2. Yeung JT, Wan P, Chen W. Guanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report. Clin Psychopharmacol Neurosci. 2026; 24(2): 419-24.
Deliberate self-harm (DSH) in adolescents presents a significant clinical challenge, particularly when compounded by comorbidities such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), borderline personality disorder (BPD), and post-traumatic stress disorder (PTSD). We describe a case of a 16-year-old transgender Māori male with ADHD, ASD traits, BPD, and PTSD, who presented with persistent mental restlessness experienced as intrusive DSH ideation. He had limited benefit and intolerable side effects with atomoxetine but responded to guanfacine modified-release. Guanfacine modified-release (1 mg nocte) treatment coincided with a marked reduction in mental restlessness and intrusive DSH ideation. During the follow-up period, there was a decrease in acute healthcare utilisation. Then the patient self-ceased guanfacine, coinciding with a return of DSH ideation and behaviours. We hypothesise that the ADHD-related mental restlessness was associated with intrusive DSH ideation; amelioration of mental restlessness and self-harm ideation by guanfacine can be interpreted as the ‘dechallenge’ phase of a ‘challenge-dechallenge’ natural experiment. This case provides novel evidence for the potential therapeutic role of guanfacine in mitigating persistent self-harm thoughts, via modulation of mental restlessness and impulsivity. Our observation provides preliminary evidence of the potential benefit of guanfacine in treating DSH, in the context of patients with co-occurring cognitive rigidity, trauma exposure, and emotional dysregulation. This case aligns with emerging evidence for the efficacy of guanfacine for ASD and trauma-related disorders, but is the first – in the existing literature – for ADHD and trauma history in an adolescent with BPD and transgender intersectionality.
